Therapeutic exploitation of necroptosis for cancer therapy
1Institute for Experimental Cancer Research in Pediatrics, Goethe-University, Komturstr. 3a, 60528 Frankfurt, Germany.
Abstract:
Evasion of programmed cell death represents one of the hallmarks of cancers that contributes to tumor initiation, progression and treatment resistance. This calls for novel therapeutic concepts to reactivate cell death programs in human malignancies. Since necroptosis represents a regulated form of necrosis that is under the control of defined signal transduction pathways, it offers molecular targets for rational therapeutic intervention. Indeed, there is mounting evidence showing that many currently used anticancer agents can engage necroptotic signaling pathways and thereby elicit cell death in malignant cells. A better understanding of the signaling networks regulating necroptosis in cancer cells is expected to speed up the development of anticancer drugs for therapeutic exploitation of necroptosis for cancer therapy.
Insights
Cancer cells evade cell death, driving tumor growth and treatment resistance. Targeting necroptosis, a regulated cell death pathway, offers a promising therapeutic strategy for cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Cell Death Research
Background:
- Evasion of programmed cell death is a key hallmark of cancer, contributing to tumor initiation, progression, and resistance to therapy.
- This necessitates the development of novel therapeutic strategies to re-establish cancer cell death programs.
- Necroptosis, a regulated form of necrosis, presents a viable target for therapeutic intervention due to its defined signaling pathways.
Purpose of the Study:
- To explore the potential of targeting necroptosis for cancer therapy.
- To understand the molecular mechanisms underlying necroptosis in cancer cells.
- To identify novel therapeutic targets for exploiting necroptosis in human malignancies.
Main Methods:
- Review of existing literature on programmed cell death and necroptosis in cancer.
- Analysis of signaling pathways regulating necroptosis.
- Investigation of anticancer agents that can induce necroptosis.
Main Results:
- Evidence suggests that several anticancer drugs can activate necroptotic signaling pathways.
- These pathways can lead to cell death in malignant cells.
- Understanding these networks is crucial for drug development.
Conclusions:
- Reactivating cell death programs, particularly necroptosis, is a promising therapeutic avenue for cancer.
- Further research into necroptosis signaling networks will accelerate the development of novel cancer therapies.
- Targeting necroptosis offers a rational approach to overcome treatment resistance in malignancies.
Related Concept Videos
01:16Necrosis
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
01:30Overview of Cell Death
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:17The Extrinsic Apoptotic Pathway